One of the key advances in regenerative medicine has been the engraftment of external epithelial stem cells to supplement or replace damaged native cells. However, the difficulty in engrafting internal tissues has hindered the long-term rescue of diseased internal epithelia, such as those in the respiratory airways. Read More
Both oxidative stress and inflammation are the main hallmarks in the development of heart failure. Researchers from the Hefei University of Technology have reported on the discovery and optimization of a series of pterostilbene derivatives intended to be used in heart failure. Read More
Researchers from China Pharmaceutical University have reported the discovery of novel spleen tyrosine kinase (SYK) inhibitors as potential candidates for the treatment of hematological malignancies. Read More
Harbour Biomed Ltd. has received FDA clearance of its IND application to commence a phase I trial of HBM-9033 in advanced solid tumors. Developed in collaboration with Medilink Therapeutics (Suzhou) Co. Ltd., HBM-9033 is an antibody-drug conjugate that specifically targets human mesothelin (MSLN), an upregulated tumor-associated antigen in various solid tumors, including mesothelioma, ovarian cancer, lung cancer, breast cancer and pancreatic cancers. The fully human monoclonal antibody in HBM-9033, generated from the Harbour Mice platform, binds preferably to membrane bond MSLN over soluble MSLN, which minimizes the interference of the shedding MSLN on the binding and internalization of the membrane bond MSLN. Read More
Researchers at Jiangsu Hengrui Medicine Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Pharmaceutical Co. Ltd. have disclosed antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting IL-4R covalently linked to glucocorticoid analogues through a linker. They are reported to be useful for the treatment of asthma and skin allergy. Read More
Researchers from Jinggangshan University reported on the synthesis of a series of novel celastrol derivatives that led to the identification of [I] as the main compound with water solubility of 11.8 mg/mL and antiproliferative effects accounting for IC50 values of 0.58, 0.32, 0.32, 0.75, 0.29 and 4.30 µM against BEL-7402, AGS, HCT 116, HepG-2, MGC-803 and A549 human cancer cell lines, respectively. Read More
Merck Sharp & Dohme Corp. has synthesized plasma kallikrein (KLKB1) inhibitors reported to be useful for the treatment of hereditary angioedema, diabetic macular edema, retinal vein occlusion, diabetic retinopathy, wet macular degeneration (exudative) and uveitis. Read More
Researchers from Nanjing Medical University have published data from a study that aimed to assess the potential of targeting fascin homologue 1 (FSCN1) as novel therapeutic strategy for the treatment of ocular neovascularization. Read More
Janssen Pharmaceutica NV has divulged pyrazolopyrimidines acting as spermine oxidase (polyamine oxidase 1; SMOX) inhibitors reported to be useful for the treatment of colorectal cancer. Read More
Eikonizo Therapeutics Inc. has described histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer, multiple sclerosis, systemic lupus erythematosus, neurodegeneration, obesity, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, among others. Read More
Verastem Oncology Inc. has entered into a discovery and development collaboration with Genfleet Therapeutics (Shanghai) Ltd. to advance three oncology discovery programs targeting RAS pathway-driven cancers. Read More
